Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Executive summary

Burden of metastatic uveal melanoma

4 evidence topics · 42 sources

Summary: epidemiology and the HLA-A∗02:01-negative share

From 1975 to 2020, the mean age-adjusted incidence of primary uveal melanoma in the United States was 5.6 per million population (6.3 per million in males and 5.0 in females), 98% of cases were in the white race, and the median age at diagnosis was 63 years. A second analysis of 37,917 cases reported an overall age-adjusted incidence of 5.54 per million, highest in non-Hispanic whites (6.87 per million) and in those aged 75 to 79 years; the National Cancer Institute gives approximately 4.3 new cases per million. Siegel et al. and the American Cancer Society estimate about 3,200 new cancers of the eye and orbit, mainly melanomas, in the United States in 2026, and Castle Biosciences estimates that approximately 2,000 patients in the U.S. are diagnosed with uveal melanoma each year. The European Medicines Agency estimated a prevalence of 0.88 per 10,000 persons in the European Union. No source states the U.S. prevalence of metastatic uveal melanoma.

Fewer than 2% of patients present with detectable metastases at diagnosis of the primary tumor according to Piperno-Neumann et al., 2% to 3% according to the National Cancer Institute, and 69 of 3610 (1.9%) in one cohort. Local therapy controls the primary tumor in more than 90% of cases, but up to 50% of patients develop metastases, mainly in the liver (90%). After treatment of choroidal melanoma, 5- and 10-year cumulative metastasis rates were 25% and 34%, and in a separate cohort the median time from initial treatment of the tumor to metastasis was 3.45 years.

Approximately 45% of people in the United States and Europe are HLA-A∗02:01-positive, and 40% to 50% of the European population express HLA-A∗02:01. In a trial of tebentafusp, HLA-A∗02:01-negative patients comprised 49% of individuals prescreened. In a deidentified multimodal database of 219 adults diagnosed with metastatic uveal melanoma from 2019 to 2025, HLA-A∗02:01 status was positive in 42.0%, negative in 42.9%, and unknown in 15.1%. Among Brazilians tested, HLA-A∗02:01 positivity by race ranged from 17.5% in black to 22.8% in indigenous individuals, lower than in North Americans and Europeans. HLA-A∗02:01 occurs at a higher frequency in uveal melanoma patients than in the general population.

Summary: natural history, survival, and mortality

Five-year relative survival for all uveal melanoma in the United States was 82.8% from 1975 to 2016; a second analysis reported 5- and 10-year relative survival of 83.3% and 73.9%, “with worse outcomes in metastatic disease”. Siegel et al. estimate 530 U.S. deaths from eye and orbit cancer in 2026. The cumulative probability of melanoma metastatic death was 0.241 at 10 years and 0.301 at 30 years, with deaths from melanoma rare beyond 20 years, and uveal melanoma-related mortality was 31% by 5 years and 52% by 35 years in a second cohort.

Following the report of metastasis from choroidal melanoma, the death rate was 80% at 1 year and 92% at 2 years, and only 8 patients survived 5 or more years. In a single cohort, median survival after metastasis was 3.9 months overall, 6.3 months with treatment, and 1.7 months without. In individual patient data from 29 trials published from 2000 to 2016, median progression-free survival was 3.3 months, the 6-month progression-free survival rate 27%, median overall survival 10.2 months, and 1-year overall survival 43%. Across 78 articles with 2494 patients, median overall survival was 1.07 years, and meta-analyses place survival beyond 5 years at an estimated 2%. With active treatment, median overall survival in one cohort was 18, 6.9, and 1.9 months in working formulation stage IVa, IVb, and IVc, respectively. Elevated lactate dehydrogenase and elevated alkaline phosphatase were the strongest prognostic factors for shorter overall survival; in another cohort, a lactate dehydrogenase level above 500 U/L carried a hazard ratio of 9.0 and liver metastases a hazard ratio of 2.09. Weinberger et al. state that it will be several years before the impact of newer systemic therapies is captured in the SEER database.

Summary: humanistic burden

In qualitative interviews with seventeen patients and 16 clinicians, most patients placed greater emphasis on the emotional than the physical impacts of disease and treatment, centred on the “existential threat posed by metastatic disease”, and described treatment burden from time commitment, travel, hospitalisation, and expense; of the treatments received, tebentafusp “conferred the heaviest inconvenience and symptom burden”. Several patients reduced or ceased employment. Anxiety increased in the days before a test until results were received, with waits of 1 day to 3 weeks. Among 475 participants followed for up to 84 months after treatment, 17.5% showed consistently elevated anxiety and 10.9% consistently elevated depression, while in a series of 708 survivors no prognostic group reported anxiety, depression, or quality of life scores beyond general population norms.

In the IMCgp100-202 trial (NCT03070392), mean EORTC QLQ-C30 global health status at baseline was 76.108 with tebentafusp and 74.872 with investigator's choice, and the mean change at end of treatment was -10.417 and -10.539; the mean change in the EQ-5D visual analogue scale at end of treatment was -10.1 and -11.7. In a randomized phase 2 trial of selumetinib versus chemotherapy (118 participants reporting), mean health-related quality of life scores did not differ significantly at any of the three time points. After percutaneous hepatic perfusion with melphalan (M-PHP), scores declined on day 2/3 and 12 of 15 scores returned to baseline by day 21 in 24 participants, and in 20 participants the median FACT-G score fell from 101.8 at baseline to 85 on day 1 and recovered to 100.3 by day 28. In the SCANDIUM trial, EQ-5D-3L health utility was 0.87 with isolated hepatic perfusion versus 0.70 with control at 6 months and 0.88 versus 0.66 at 12 months; the difference was not significant after adjustment for baseline utility.

Summary: economic burden and testing costs

In the MarketScan Commercial, Medicare, and Multi-State Medicaid databases, 471 patients with metastatic uveal melanoma (47% commercially insured, 43% Medicare, 10% Medicaid) had mean healthcare costs of $29,187 per patient per month (SD $46,089), comprising inpatient costs of $6,502 (including $4,049 for ICU admissions), outpatient medical services of $20,555, and outpatient pharmacy costs of $2,131. Among commercial and Medicare patients, mean all-cause costs per patient per month were highest with tebentafusp ($93,805); adverse event-related costs were also highest with tebentafusp ($6,746) and formed the largest share of total costs with chemotherapy (12.9%). Only half of these patients received any systemic treatment, and 19% received liver directed therapy. In HES data from April 2012 to June 2016, inpatient admissions for metastatic uveal melanoma cost NHSE £2.5 million (mean £6,084 per patient), the cohort attended 3,618 outpatient appointments and had 669 A&E visits, and 28% of patients were treated 40 km or more from home. Tebentafusp requires hospitalisation at commencement: patients treated with tebentafusp (TEBE) at one center received a median of 4 inpatient doses, and another cohort had a median of 3 cumulative inpatient nights for doses 1 to 3.

Patients and families bear travel and treatment costs: 50% of participants in the Ocumel Canada survey required some assistance with travel costs, participants in a qualitative study described worry about self-funding treatment and the financial burden on their family, and respondents with metastatic disease reported occasional dependence on a spouse, partner, child, or caregiver.

The Kentucky Department for Medicaid Services 2026 fee schedule pays $169.90 for high-resolution HLA class I typing of one allele or allele group (CPT 81381) and $177.25 for one locus (81380), and $7,776.00 for mRNA gene expression analysis of 15 genes in eye melanoma (81552). Labcorp bills its HLA-A∗02:01 test under CPT 81381 with a turnaround of 3 to 7 days, and the test has not been cleared or approved by the FDA. The DecisionDx-UM prognostic test, which Medicare covers for newly diagnosed uveal melanoma without evidence of metastasis, has a rate of $7,776 per test for 2026, and Castle Biosciences estimates a U.S. market of approximately $10 million. In the Ocumel Canada survey, 46.15% of respondents paid for their genetic testing, and some declined testing because of the cost. Strict compliance with DecisionDx-UM results was associated with a 50% reduction in surveillance procedures at two years and a 63% reduction at five years.